J Cancer 2019; 10(5):1288-1296. doi:10.7150/jca.28529 This issue Cite

Research Paper

Lower Expression of Gelsolin in Colon Cancer and Its Diagnostic Value in Colon Cancer Patients

Zhuoyu Chen1,2#, Kaifei Li1#, Xiaofeng Yin1, Haixia Li1, Yao Li1, Qiong Zhang1, Haifang Wang1✉, Yurong Qiu1,3,4✉

1. Laboratory Medicine Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
2. Department of Clinical Laboratory, Beijing University of Chinese Medicine Shenzhen Hospital, Shenzhen, Guangdong, China
3. Guangdong Key Laboratory of Biochip Technology, Southern Medical University, Guangzhou, Guangdong, China
4. Huayin Medical Laboratory Center Co., Ltd., Guangzhou, Guangdong, China
# These authors contributed equally to this work.

Citation:
Chen Z, Li K, Yin X, Li H, Li Y, Zhang Q, Wang H, Qiu Y. Lower Expression of Gelsolin in Colon Cancer and Its Diagnostic Value in Colon Cancer Patients. J Cancer 2019; 10(5):1288-1296. doi:10.7150/jca.28529. https://www.jcancer.org/v10p1288.htm
Other styles

File import instruction

Abstract

Colon cancer is one of the most common malignancies causing the majority of cancer-related deaths. Gelsolin (GSN) has been found to be dysregulated in various cancers. However, the secreted GSN in colon cancer remains largely unknown. In the present study, we explored the expression profile of GSN in colon cancer tissues and the diagnostic value of serum GSN in colon cancer. In addition, the effects of secreted GSN in colon cancer cells were studied. We thus found that immunoreactive GSN levels were significantly lower in colon cancer tissues than those in non-tumor colon tissues. Functional studies demonstrated that secreted GSN could restrain cell invasion and migration in vitro. Mechanistically, dose dependent recombinant GSN down-regulated the expression of MMP2 and MMP9, which might restrain the process of cell invasion and migration. Furthermore, serum levels of GSN were significantly lower in colon cancer patients than those in healthy volunteers, and ROC curves showed serum level of GSN had a better diagnostic value for colon cancer (AUC=0.932) than the traditional tumor biomarker Carcinoembryonic Antigen (CEA) or Carbohydrate Antigen 19-9 (CA199). In conclusion, our results suggest that the secreted GSN restrains the invasion and migration of colon cancer cells. Meanwhile, the serum GSN may be a new biomarker for the diagnosis of colon cancer.

Keywords: colon cancer, diagnosis, gelsolin, metastasis


Citation styles

APA
Chen, Z., Li, K., Yin, X., Li, H., Li, Y., Zhang, Q., Wang, H., Qiu, Y. (2019). Lower Expression of Gelsolin in Colon Cancer and Its Diagnostic Value in Colon Cancer Patients. Journal of Cancer, 10(5), 1288-1296. https://doi.org/10.7150/jca.28529.

ACS
Chen, Z.; Li, K.; Yin, X.; Li, H.; Li, Y.; Zhang, Q.; Wang, H.; Qiu, Y. Lower Expression of Gelsolin in Colon Cancer and Its Diagnostic Value in Colon Cancer Patients. J. Cancer 2019, 10 (5), 1288-1296. DOI: 10.7150/jca.28529.

NLM
Chen Z, Li K, Yin X, Li H, Li Y, Zhang Q, Wang H, Qiu Y. Lower Expression of Gelsolin in Colon Cancer and Its Diagnostic Value in Colon Cancer Patients. J Cancer 2019; 10(5):1288-1296. doi:10.7150/jca.28529. https://www.jcancer.org/v10p1288.htm

CSE
Chen Z, Li K, Yin X, Li H, Li Y, Zhang Q, Wang H, Qiu Y. 2019. Lower Expression of Gelsolin in Colon Cancer and Its Diagnostic Value in Colon Cancer Patients. J Cancer. 10(5):1288-1296.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image